The Soluble Guanylate Cyclase Activator BAY 58-2667 Protects against Morbidity and Mortality in Endotoxic Shock by Recoupling Organ Systems

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Vandendriessche, Benjamin ^a,b   Rogge, Elke ^a,b   Goossens, Vera ^a,b   Vandenabeele, Peter ^a,b   Stasch, Johannes Peter ^c   Brouckaert, Peter ^a,b   Cauwels, Anje ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c Institute of Cardiovascular Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CINACIGUAT; CYCLIC GMP; ESCHERICHIA COLI ENDOTOXIN; GUANYLATE CYCLASE; INTERLEUKIN 6; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SILDENAFIL; SOLUBLE GUANYLATE CYCLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG BINDING; DRUG INTERACTION; DRUG SELECTIVITY; FEMALE; HEART RATE; HYPOTHERMIA; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; ORGAN SYSTEMS; POST TREATMENT SURVIVAL; PROTEIN BLOOD LEVEL; RECOUPLING ORGAN SYSTEMS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; APOPTOSIS; BENZOATES; BLOOD PRESSURE; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ENZYME ACTIVATORS; FEMALE; GUANYLATE CYCLASE; HEART RATE; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; PYRAZOLES; PYRIDINES; SHOCK, SEPTIC; SULFONES;

EID: 84883144236     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072155     Document Type: Article

References (38)

1. Martin GS, Mannino DM, Eaton S, Moss M, (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554.
2. Nguyen HB, Rivers EP, Abrahamian FM, Moran GJ, Abraham E, et al. (2006) Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann Emerg Med 48: 28-54.
3. Dellinger PR, Joseph PE, (2004) Mediator modulation therapy of severe sepsis and septic shock: does it work? Crit Care Med 32: 282-286.
4. Riedemann NC, Guo R, Ward PA, (2003) Novel strategies for the treatment of sepsis. Nat Med 9: 517-524.
5. Ranieri VM, Thompson BT, Barie PS, Dhainaut J-F, Douglas IS, et al. (2012) Drotrecogin alfa (activated) in adults with septic shock. New Engl J Med 366: 2055-2064.
6. Godin PJ, Buchman TG, (1996) Uncoupling of biological oscillators: a complementary hypothesis concerning the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 24: 1107-1116.
7. Seely J, Christou NV, (2000) Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. Crit Care Med 28: 2193-2200.
8. Schmidt HB, Werdan K, Müller-Werdan U, (2001) Autonomic dysfunction in the ICU patient. Crit Care Med 7: 314-322.
9. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, et al. (2000) Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52: 375-414.
10. Münzel T, Feil R, Mülsch A, Lohmann SM, Hofmann F, et al. (2003) Physiology and pathophysiology of vascular signaling controlled by guanosine 3′,5′-cyclic monophosphate-dependent protein kinase. Circ 108: 2172-2183.
11. Cauwels A, Buys ES, Thoonen R, Geary L, Delanghe J, et al. (2009) Nitrite protects against morbidity and mortality associated with TNF- or LPS-induced shock in a soluble guanylate cyclase-dependent manner. J Exp Med 206: 2915-2924.
12. Buys ES, Cauwels A, Raher MJ, Passeri JJ, Hobai I, et al. (2009) sGC(alpha)1(beta)1 attenuates cardiac dysfunction and mortality in murine inflammatory shock models. J Physiol 297: H654-63.
13. Meurer S, Pioch S, Pabst T, Opitz N, Schmidt PM, et al. (2009) Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res 105: 33-41.
14. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HHHW, et al. (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Disc 5: 755-768.
15. Stasch J-P, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, et al. (2006) Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552-2561.
16. Stasch J-P, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, et al. (2002) NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136: 773-783.
17. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, et al. (2001) NO-independent regulatory site on soluble guanylate cyclase. Nature 410: 212-215.
18. Schmidt HHHW, Schmidt PM, Stasch J-P, (2009) NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 1: 309-339.
19. Stasch J, Hobbs AJ, (2009) NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 1: 277-308.
20. Corbin JD, Francis SH, (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 274: 13729-13732.
21. Cauwels A, Brouckaert P, (2007) Survival of TNF toxicity: dependence on caspases and NO. Arch Biochem Biophys 462: 132-139.
22. Kumar a, Haery C, Parrillo JE, (2001) Myocardial dysfunction in septic shock: Part I. Clinical manifestation of cardiovascular dysfunction. J Cardiothorac Vasc Anesth 15: 364-376.
23. Groneberg D, König P, Wirth A, Offermanns S, Koesling D, et al. (2010) Smooth muscle-specific deletion of nitric oxide-sensitive guanylyl cyclase is sufficient to induce hypertension in mice. Circ 121: 401-409.
24. Mergia E, Friebe A, Dangel O, Russwurm M, Koesling D, (2006) Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system. J Clin Invest 116: 1731-1737.
25. Kawasaki M, Kuwano K, Hagimoto N, Matsuba T, Kunitake R, et al. (2000) Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspase inhibitor. Am J Pathol 157: 597-603.
26. Cauwels A, Janssen B, Waeytens A, Cuvelier C, Brouckaert P, (2003) Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2. Nat Immunol 4: 387-393.
27. Frey R, Mück W, Unger S, Artmeier-Brandt U, Weimann G, et al. (2008) Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J Clin Pharmacol 48: 1400-1410.
28. Radaelli A, Castiglioni P, Cerrito MG, De Carlini C, Soriano F, et al. (2012) Infusion of E. Coli Lipopolysaccharides Toxin in Rats Produces an Early and Severe Impairment of Baroreflex Function in Absence of Blood Pressure Changes. Shock.
29. Meyer M, Stiedl O, (2006) Fractal rigidity by enhanced sympatho-vagal antagonism in heartbeat interval dynamics elicited by central application of corticotropin-releasing factor in mice. J Math Biol 52: 830-874.
30. Fukutani T, Iino S, Nojyo Y, (2009) The expression of soluble guanylate cyclase in the vasculature of rat skeletal muscle. Arch Hist Cyt 72: 117-126.
31. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, et al. (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34: 1589-1596.
32. Cauwels A, Rogge E, Janssen B, Brouckaert P, (2010) Reactive oxygen species and small-conductance calcium-dependent potassium channels are key mediators of inflammation-induced hypotension and shock. J Mol Med 88: 921-930.
33. Brouckaert PG, Libert C, Everaerdt B, Takahashi N, Fiers W, (1989) A role for interleukin 1 in the in vivo actions of tumor necrosis factor. Lymphokine Res 8: 269-274.
34. Just A, Faulhaber J, Ehmke H, (2000) Autonomic cardiovascular control in conscious mice. Am J Physiol 279: R2214-21.
35. Burr RL, (2007) Interpretation of normalized spectral heart rate variability indices in sleep research: a critical review. Sleep 30: 913-919.
36. Peng CK, Havlin S, Stanley HE, Goldberger AL, (1995) Quantification of scaling exponents and crossover phenomena in nonstationary heartbeat time series. Chaos 5: 82-87.
37. Goldberger AL, Amaral LA, Glass L, Hausdorff JM, Ivanov PC, et al. (2000) PhysioBank, PhysioToolkit, and PhysioNet: components of a new research resource for complex physiologic signals. Circ 101: E215-20.
38. Kaplan D (n.d.) HRV software. Available: http://www.macalester.edu/~kaplan. Accessed 2013, July 6.